We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

11 hedge funds and large institutions have $2.61M invested in Scinai Immunotherapeutics in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

278% more capital invested

Capital invested by funds: $689K → $2.61M (+$1.92M)

38% more funds holding

Funds holding: 8 → 11 (+3)

2.11% more ownership

Funds ownership: 0.57% → 2.69% (+2.1%)

Holders
11
Holders Change
+3
Holders Change %
+37.5%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HighTower Advisors
HighTower Advisors
Illinois
+$107K
2
PVH
Psagot Value Holdings
Israel
+$69.2K
3
Renaissance Technologies
Renaissance Technologies
New York
+$62.9K
4
Deutsche Bank
Deutsche Bank
Germany
+$56.6K
5
VIA
Vantage Investment Advisors
Pennsylvania
+$12.6K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$139K

SCNI Hedge Fund Activity: Q4 2017 in Review

11 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2017, worth a combined $2.61M — up 278% from $689K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new SCNI positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was HighTower Advisors, opening a new position worth an estimated $107K. The largest seller was Sabby Management, exiting entirely with an estimated $139K sold.

  • 11 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2017, up from 8 in Q3 2017.
  • Funds reported $2.61M of Scinai Immunotherapeutics stock for Q4 2017, up 278% quarter-over-quarter.
  • 4 funds opened new Scinai Immunotherapeutics positions in Q4 2017 and 1 closed out, a net change of +3 holders.
  • The largest Scinai Immunotherapeutics buyer in Q4 2017 was HighTower Advisors, an estimated $107K added.
  • The largest Scinai Immunotherapeutics seller in Q4 2017 was Sabby Management, an estimated $139K sold.

Based on aggregated 13F filings for Q4 2017.